YS Biopharma Co., Ltd. (YS)

Market Cap	149.72M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	188.33M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,379
Open	0.810
Previous Close	0.810
Day's Range	0.711 - 0.850
52-Week Range	0.350 - 1.970
Beta	0.55
Analysts	Buy
Price Target	5.25 (+560.38%)
Earnings Date	Apr 19, 2024

About YS

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 773
• Stock Exchange: NASDAQ
• Ticker Symbol: YS

Financial Performance

In 2022, YS's revenue was 687.20 million, an increase of 36.63% compared to the previous year's 502.95 million. Losses were -421.46 million, 14.7% more than in 2021.

Financial numbers in CNY

Analyst Forecast

According to one analyst, the rating for YS stock is "Buy" and the 12-month stock price forecast is $5.25.

Price Target

$5.25

(560.38% upside)

Analyst Consensus: Buy